Findings show 17-minute drop in moderate-to-vigorous physical activity based on global systematic literature review
Adverse Reactions to BNT162b2 Mild, Moderate for 5- to 11-Year-Olds
Based on data from three U.S. safety monitoring systems, adverse events were mild-to-moderate, and myocarditis occurred rarely
Prevalence of COVID-19-Related Croup Up During Omicron
Odds of hospitalization not significantly different during periods with alpha or other variant predominance, delta predominance, versus omicron-predominant periods
Provider Availability Linked to COVID-19 Vaccine Uptake in Children
Vaccination coverage for children aged 5 to 11 higher in counties with at least one active COVID-19 vaccine provider versus no provider
Two Doses of BNT162b2 Moderately Effective for 5- to 11-Year-Olds
Moderate effectiveness against documented infection and symptomatic COVID-19 for those vaccinated on or after Nov. 23, 2021
ACIP Recommends COVID-19 Vaccines for Children Aged ≥6 Months
ACIP interim recommendations presented for Moderna, Pfizer-BioNTech mRNA vaccines for children aged 6 months to 5 years
Symptoms May Persist After Pediatric SARS-CoV-2 Infection
Large cross-sectional study offers survey of long COVID symptoms in children who have had SARS-CoV-2 infection
CDC Backs Moderna Vaccine for Those Aged 6 to 17
ACIP endorsed the shots after hearing the latest evidence on the vaccine’s effectiveness
Pediatric Emergency Encounters for Physical Abuse Down During Pandemic
Rates of lower-severity encounters reduced, but no decrease seen in rates of higher-severity encounters
With CDC Approval, COVID-19 Shots for Under 5s Ready for Delivery
Health officials have said the federal government will be ready to ship doses out this week